A detailed history of Atria Investments LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Atria Investments LLC holds 127,858 shares of BMY stock, worth $7.45 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
127,858
Previous 116,947 9.33%
Holding current value
$7.45 Million
Previous $4.86 Million 36.24%
% of portfolio
0.09%
Previous 0.07%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$39.66 - $51.75 $432,730 - $564,644
10,911 Added 9.33%
127,858 $6.62 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $881,112 - $1.16 Million
-21,891 Reduced 15.77%
116,947 $4.86 Million
Q1 2024

May 21, 2024

BUY
$47.98 - $54.4 $780,634 - $885,088
16,270 Added 13.27%
138,838 $7.53 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $1.07 Million - $1.27 Million
-21,995 Reduced 15.21%
122,568 $6.29 Million
Q3 2023

Nov 07, 2023

SELL
$57.89 - $64.73 $909,799 - $1.02 Million
-15,716 Reduced 9.81%
144,563 $8.39 Million
Q2 2023

Aug 04, 2023

BUY
$63.71 - $70.74 $471,581 - $523,617
7,402 Added 4.84%
160,279 $10.2 Million
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $1.31 Million - $1.48 Million
19,862 Added 14.93%
152,877 $10.6 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $9,655 - $11,433
-141 Reduced 0.11%
133,015 $9.57 Million
Q3 2022

Nov 01, 2022

SELL
$0.13 - $76.84 $575 - $340,324
-4,429 Reduced 3.22%
133,156 $9.47 Million
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $217,496 - $239,540
-2,995 Reduced 2.13%
137,585 $10.6 Million
Q1 2022

May 02, 2022

BUY
$61.48 - $73.72 $1.61 Million - $1.93 Million
26,188 Added 22.89%
140,580 $10.3 Million
Q4 2021

Feb 04, 2022

BUY
$53.63 - $62.52 $1.01 Million - $1.17 Million
18,779 Added 19.64%
114,392 $7.13 Million
Q3 2021

Nov 16, 2021

BUY
$59.17 - $69.31 $172,421 - $201,969
2,914 Added 3.14%
95,613 $5.66 Million
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $211,546 - $230,374
-3,417 Reduced 3.56%
92,699 $6.19 Million
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $58,449 - $65,738
985 Added 1.04%
96,116 $6.07 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $952,017 - $1.08 Million
-16,488 Reduced 14.77%
95,131 $5.9 Million
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $1.09 Million - $1.21 Million
19,057 Added 20.59%
111,619 $6.73 Million
Q2 2020

Sep 22, 2020

BUY
$54.82 - $64.09 $5.07 Million - $5.93 Million
92,562 New
92,562 $5.44 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $7.47 Million - $10.9 Million
-161,017 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$49.21 - $64.19 $5.53 Million - $7.22 Million
112,445 Added 231.5%
161,017 $10.3 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $228,776 - $271,247
-5,349 Reduced 9.92%
48,572 $2.46 Million
Q2 2019

Aug 26, 2019

BUY
$44.62 - $49.34 $2.41 Million - $2.66 Million
53,921 New
53,921 $2.51 Million
Q2 2019

Aug 09, 2019

SELL
$44.62 - $49.34 $1.56 Million - $1.73 Million
-34,973 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $376,030 - $448,369
8,334 Added 31.28%
34,973 $1.67 Million
Q4 2018

Feb 12, 2019

SELL
$48.76 - $63.23 $1.3 Million - $1.68 Million
-26,625 Reduced 49.99%
26,639 $1.39 Million
Q3 2018

Oct 09, 2018

BUY
$55.19 - $62.25 $66,338 - $74,824
1,202 Added 2.31%
53,264 $3.31 Million
Q2 2018

Jul 13, 2018

SELL
$50.53 - $62.98 $35,522 - $44,274
-703 Reduced 1.33%
52,062 $2.88 Million
Q1 2018

Apr 30, 2018

BUY
$59.92 - $68.98 $251,903 - $289,991
4,204 Added 8.66%
52,765 $3.34 Million
Q4 2017

Jan 16, 2018

BUY
$59.94 - $65.35 $425,214 - $463,592
7,094 Added 17.11%
48,561 $2.98 Million
Q3 2017

Oct 12, 2017

BUY
$55.23 - $63.74 $2.29 Million - $2.64 Million
41,467
41,467 $2.64 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Atria Investments LLC Portfolio

Follow Atria Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atria Investments LLC with notifications on news.